{"id":"antimalarials","rwe":[],"tags":[],"phase":"phase_1","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT07470424","NCT01093989","NCT03504540","NCT03963869","NCT04327310","NCT00730366","NCT02996695","NCT01150344","NCT01843764","NCT05676645","NCT01907672","NCT00142246","NCT01728961","NCT00119145","NCT01055002","NCT04726553","NCT02511054","NCT06601712","NCT00146731","NCT00509015","NCT01205178","NCT01196091","NCT02974348","NCT01713621","NCT02885610","NCT01755559","NCT02867059","NCT07235020","NCT02504918","NCT01849640","NCT02115516","NCT02894294","NCT00126971","NCT02895568","NCT04634695","NCT00341003","NCT01632241","NCT00203736","NCT01680406","NCT00158548","NCT05924776","NCT01156389","NCT02544048","NCT04706130","NCT04864444","NCT06965244","NCT01442168","NCT07488520","NCT04389320","NCT05192265"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"brandName":"Antimalarials","companyId":"university-of-oxford","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"University of Oxford","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Antimalarials","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07470424","phase":"Phase 1","title":"A Randomized, Open-Label Crossover Study to Evaluate Potential Pharmacokinetic Interactions of Orally Administered Piperaquine, Pyronaridine and Artesunate in Healthy Adult Participants","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","isPivotal":false,"enrollment":24,"indication":"Malaria","completionDate":"2027-08-01"},{"nctId":"NCT01093989","phase":"NA","title":"Acute vs. Delayed Iron Therapy: Effect on Iron Status, Anemia and Cognition","status":"COMPLETED","sponsor":"University of Minnesota","isPivotal":false,"enrollment":239,"indication":"Anemia, Inflammation","completionDate":"2014-12"},{"nctId":"NCT03504540","phase":"N/A","title":"Comparison of Complement Factors and Genetic Polymorphisms of AMD Between Patients With Systemic Lupus Erythematosus (SLE) With and Without Retinal \"Pseudo-drusen-like\" Deposits: Case-control Study (P","status":"COMPLETED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","isPivotal":false,"enrollment":42,"indication":"Lupus Erythematosus, Lupus Erythematosus, Systemic","completionDate":"2021-05-15"},{"nctId":"NCT03963869","phase":"NA","title":"A Quasi-Experimental Study to Assess the Effectiveness of Malaria Camps as Part of the Odisha State Malaria Elimination Drive","status":"COMPLETED","sponsor":"NYU Langone Health","isPivotal":false,"enrollment":2463,"indication":"Malaria","completionDate":"2021-03-31"},{"nctId":"NCT04327310","phase":"Phase 1","title":"A Phase 1, 3 Part, Randomized, Placebo Controlled, Ascending Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of Single Intravenous Doses of Meplazumab and to Assess Its Antimalarial Ac","status":"WITHDRAWN","sponsor":"Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd","isPivotal":false,"enrollment":0,"indication":"Malaria (Plasmodium Falciparum)","completionDate":"2024-03"},{"nctId":"NCT00730366","phase":"Phase 3","title":"New Approaches to Improve Coverage and Compliance of Antimalarial Treatment for Pregnant Women in Rural Africa.","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","isPivotal":true,"enrollment":2766,"indication":"Malaria in Pregnancy","completionDate":"2006-12"},{"nctId":"NCT02996695","phase":"Phase 1","title":"Safety, Tolerability, Immunogenicity and Protective Efficacy Against Naturally-Transmitted Malaria of Infectious, Cryopreserved Plasmodium Falciparum Sporozoites (PfSPZ Challenge) Administered by Dire","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":62,"indication":"Plasmodium Falciparum Infection","completionDate":"2018-06-22"},{"nctId":"NCT01150344","phase":"Phase 4","title":"Effectiveness and Safety Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria : a Multicentric Study","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","isPivotal":false,"enrollment":317,"indication":"Malaria","completionDate":"2015-11"},{"nctId":"NCT01843764","phase":"N/A","title":"Efficacy of Plasmodium Falciparum Specific Rapid Diagnostic Tests for Assessment of Initial Clearance and Detection of Recurrent Infections After Antimalarial Treatment","status":"COMPLETED","sponsor":"Anders Björkman","isPivotal":false,"enrollment":53,"indication":"Plasmodium Falciparum Malaria","completionDate":"2012-06"},{"nctId":"NCT05676645","phase":"N/A","title":"Pharmacokinetics of Drugs Used to Treat Uncomplicated Malaria in Breastfeeding Mother-infant Pairs: An Observational Pharmacokinetic Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Liverpool","isPivotal":false,"enrollment":30,"indication":"Malaria,Falciparum","completionDate":"2026-12-25"},{"nctId":"NCT01907672","phase":"Phase 4","title":"The Role of Rapid Diagnostic Tests for Malaria for Targeting of ACTs at Community Level: a Cluster Randomized Trial","status":"COMPLETED","sponsor":"Ghana Health Services","isPivotal":false,"enrollment":4748,"indication":"Malaria","completionDate":"2013-04"},{"nctId":"NCT00142246","phase":"Phase 3","title":"Intermittent Preventive Treatment in Schools: a Randomised Controlled Trial of the Impact of IPT on Malaria, Anaemia and Education Amongst Schoolchildren in Western Kenya","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","isPivotal":true,"enrollment":6758,"indication":"Malaria, Falciparum","completionDate":"2006-04"},{"nctId":"NCT01728961","phase":"Phase 4","title":"Pharmacology of Artemisinin-Based Antimalarial Therapy Within the Context of Antiretroviral Therapy","status":"TERMINATED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","isPivotal":false,"enrollment":19,"indication":"HIV Infection, Malaria","completionDate":"2014-03"},{"nctId":"NCT00119145","phase":"Phase 4","title":"A Non-Inferiority, Open-Labelled, Randomised Trial Of The Efficacy And Safety Of Artesunate-Amodiaquine, Artemether-Lumefantrine, And Artesunate-Lapdap For Treatment Of Uncomplicated P. Falciparum Mal","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","isPivotal":false,"enrollment":510,"indication":"Malaria","completionDate":"2006-05"},{"nctId":"NCT01055002","phase":"Phase 1","title":"A Pilot Phase II Study of the Efficacy of Antimalarial Drugs Against Plasmodium Falciparum by Experimental Challenge With a Low Dose of Blood Stage Parasites in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","isPivotal":false,"enrollment":16,"indication":"Healthy, Non-smokers","completionDate":"2010-08"},{"nctId":"NCT04726553","phase":"EARLY/Phase 1","title":"Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in Patients With Moderately to Severely Active Systemic Lupus Erythematosus: A Multi-Centre Open Label Parallel Group Trial:","status":"UNKNOWN","sponsor":"Oklahoma Medical Research Foundation","isPivotal":false,"enrollment":20,"indication":"Systemic Lupus Erythematosus (SLE)","completionDate":"2024-12-31"},{"nctId":"NCT02511054","phase":"Phase 1","title":"Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Tr","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":57,"indication":"Malaria","completionDate":"2017-06-01"},{"nctId":"NCT06601712","phase":"Phase 4","title":"Delivery Strategies for Malaria Chemoprevention in the Post-discharge Management of Children Hospitalised With Severe Anaemia or Severe Malaria: a Cluster Randomised Controlled Implementation Trial in","status":"RECRUITING","sponsor":"Institut de Recherche Clinique du Benin","isPivotal":false,"enrollment":648,"indication":"Severe Malaria, Severe Anaemia","completionDate":"2026-12-31"},{"nctId":"NCT00146731","phase":"Phase 3","title":"Treating Malaria During Pregnancy: A Randomized Trial of Potential Options for Treatment in an Area of High Drug Resistance in Tanzania","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","isPivotal":true,"enrollment":310,"indication":"Malaria","completionDate":"2007-09"},{"nctId":"NCT00509015","phase":"NA","title":"Mass-Drug Administration With a Gametocytocidal Drug Combination, a Model for a Transmission Blocking Vaccine","status":"COMPLETED","sponsor":"Radboud University Medical Center","isPivotal":false,"enrollment":6000,"indication":"Malaria, Falciparum","completionDate":"2008-08"},{"nctId":"NCT01205178","phase":"Phase 1","title":"A Phase I Study to Investigate the Hemolytic Potential of Tafenoquine in Healthy Subjects With Glucose-6-phosphate Dehydrogenase Deficiency and the Safety and Tolerability of Tafenoquine in Acute Plas","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":192,"indication":"Malaria","completionDate":"2013-04-01"},{"nctId":"NCT01196091","phase":"Phase 3","title":"A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":true,"enrollment":1164,"indication":"Systemic Lupus Erythematosus, Connective Tissue Disease","completionDate":"2015-06"},{"nctId":"NCT02974348","phase":"Phase 3","title":"Assessment of Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa","status":"COMPLETED","sponsor":"University of Bamenda","isPivotal":true,"enrollment":300,"indication":"Drug Resistant Malaria Due to Plasmodium Falciparum","completionDate":"2014-10"},{"nctId":"NCT01713621","phase":"Phase 2","title":"The Extended Observation Over a Period of 28 Days of the Effects of Single Doses of OZ439 on the Recrudescence of Plasmodium Falciparum Malaria - a PhIIa, Open Label Study in Adult Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","isPivotal":false,"enrollment":25,"indication":"Malaria","completionDate":"2015-04"},{"nctId":"NCT02885610","phase":"Phase 2","title":"A Phase IIb , Placebo-Controlled ,Multi-Center, Randomized, Double-Blind, Dose-explorating Trial of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subject","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","isPivotal":false,"enrollment":249,"indication":"Systemic Lupus Erythematosus","completionDate":"2019-07-09"},{"nctId":"NCT01755559","phase":"Phase 4","title":"Efficacy of Artesunate-amodiaquine, Dihydroartemisinin-piperaquine and Artemether-lumefantrine Combination Therapies for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Aged 6","status":"COMPLETED","sponsor":"Epicentre","isPivotal":false,"enrollment":663,"indication":"Malaria","completionDate":"2014-11"},{"nctId":"NCT02867059","phase":"Phase 1","title":"A Proof-of-concept Study to Assess the Effect of (+)-SJ000557733 (SJ733) Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","isPivotal":false,"enrollment":17,"indication":"Plasmodium Falciparum Malaria","completionDate":"2016-12-22"},{"nctId":"NCT07235020","phase":"Phase 2","title":"A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Participan","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":52,"indication":"Uncomplicated Plasmodium Falciparum Malaria","completionDate":"2025-02-21"},{"nctId":"NCT02504918","phase":"N/A","title":"Markers of T Cell Suppression: Associations With Malaria Infection and Antimalarial Treatment","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":200,"indication":"Malaria","completionDate":"2018-06-12"},{"nctId":"NCT01849640","phase":"NA","title":"Active Surveillance for P. Falciparum Drug Resistance With Assessment of Transmission Blocking Activity of Single Dose Primaquine in Cambodia","status":"SUSPENDED","sponsor":"David Saunders","isPivotal":false,"enrollment":150,"indication":"Uncomplicated Plasmodium Falciparum Malaria","completionDate":"2016-06"},{"nctId":"NCT02115516","phase":"Phase 1","title":"Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis","status":"COMPLETED","sponsor":"Sanaria Inc.","isPivotal":false,"enrollment":67,"indication":"Malaria, Plasmodium Falciparum Malaria","completionDate":"2016-04"},{"nctId":"NCT02894294","phase":"N/A","title":"Measuring the Impact of Seasonal Malaria Chemoprevention as Part of Routine Malaria Control in Kita, Mali","status":"COMPLETED","sponsor":"University of Bamako","isPivotal":false,"enrollment":1162,"indication":"Malaria, Anemia","completionDate":"2015-06"},{"nctId":"NCT00126971","phase":"Phase 1","title":"Pharmacokinetics of Chlorproguanil-Dapsone in Pregnant Women With Plasmodium Falciparum Infection, and Reinfection With P. Falciparum During Pregnancy Following Treatment","status":"TERMINATED","sponsor":"Centers for Disease Control and Prevention","isPivotal":false,"enrollment":132,"indication":"Malaria","completionDate":""},{"nctId":"NCT02895568","phase":"N/A","title":"Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers in Komé, Doba, Republic of Chad","status":"COMPLETED","sponsor":"University of Oxford","isPivotal":false,"enrollment":399,"indication":"Plasmodium Falciparum","completionDate":"2018-09-06"},{"nctId":"NCT04634695","phase":"N/A","title":"Assessing the Prevalence and Impact of Dihydropteroate Synthase-431V Mutation on the Protective Efficacy of Intermittent Preventive Treatment During Pregnancy Using Sulphadoxine-pyrimethamine","status":"UNKNOWN","sponsor":"Obafemi Awolowo University","isPivotal":false,"enrollment":288,"indication":"Pregnancy Malaria","completionDate":"2021-07-01"},{"nctId":"NCT00341003","phase":"N/A","title":"Multidisciplinary Studies of Severe Malaria and Antimalarial Drug Resistance in Cambodia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":2090,"indication":"Severe Malaria, Malaria","completionDate":"2011-01-14"},{"nctId":"NCT01632241","phase":"Phase 4","title":"A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Er","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","isPivotal":false,"enrollment":503,"indication":"Systemic Lupus Erythematosus","completionDate":"2019-01-28"},{"nctId":"NCT00203736","phase":"NA","title":"Open Label Drug Study (With Single and Parallel Group Components) to Evaluate Combination Antimalarial Therapy for Efficacy, Gametocyte Carriage and Molecular Markers Associated With SP Resistance in ","status":"COMPLETED","sponsor":"University of Cape Town","isPivotal":false,"enrollment":240,"indication":"Malaria","completionDate":"2003-10"},{"nctId":"NCT01680406","phase":"Phase 4","title":"Ethiopia Antimalarial in Vivo Efficacy Study 2012: Evaluating the Efficacy of Artemether-lumefantrine Alone Compared to Artemether-lumefantrine Plus Primaquine and Chloroquine Alone Compared to Chloro","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","isPivotal":false,"enrollment":398,"indication":"Plasmodium Vivax Infection","completionDate":"2014-12"},{"nctId":"NCT00158548","phase":"Phase 3","title":"Studies on Adding Artesunate to Existing Antimalarial Therapies With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","isPivotal":true,"enrollment":650,"indication":"Malaria, Falciparum Malaria","completionDate":"2004-12"},{"nctId":"NCT05924776","phase":"Phase 2","title":"Clinical Study of Plasmodium Immunotherapy for Advanced Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.","isPivotal":true,"enrollment":30,"indication":"Advanced Ovarian Cancer","completionDate":"2029-03-30"},{"nctId":"NCT01156389","phase":"Phase 1","title":"Open-label, Randomised, Drug Interaction Study of Pyramax (Pyronaridine Artesunate) and the Protease Inhibitor Ritonavir in Healthy Volunteers","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","isPivotal":false,"enrollment":34,"indication":"Malaria","completionDate":"2010-09"},{"nctId":"NCT02544048","phase":"N/A","title":"Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":49,"indication":"Malaria","completionDate":"2017-08-11"},{"nctId":"NCT04706130","phase":"Phase 4","title":"Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","isPivotal":false,"enrollment":160,"indication":"Vivax Malaria","completionDate":"2024-10-01"},{"nctId":"NCT04864444","phase":"NA","title":"Mass Drug Administration With Dihydroartemisinin-piperaquine and Primaquine to Reduce Malaria in a Moderate-low Transmission Setting in Senegal: A Cluster Randomized Controlled Trial","status":"COMPLETED","sponsor":"University of California, San Francisco","isPivotal":false,"enrollment":10715,"indication":"Malaria,Falciparum, Malaria","completionDate":"2023-06-30"},{"nctId":"NCT06965244","phase":"Phase 3","title":"Lenalidomide vs mEthotrexate in dIfficult-to-treat cutaneouS lUpus eRythEmatosus : An Assessor-blinded Randomized Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","isPivotal":true,"enrollment":122,"indication":"Cutaneous Lupus Erythematosus (CLE)","completionDate":"2029-04-01"},{"nctId":"NCT01442168","phase":"Phase 1","title":"A Phase I/II, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study of Sevuparin/DF02, as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria","status":"TERMINATED","sponsor":"Modus Therapeutics AB","isPivotal":false,"enrollment":53,"indication":"Malaria, Falciparum","completionDate":"2014-01"},{"nctId":"NCT07488520","phase":"Phase 4","title":"Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire","status":"NOT_YET_RECRUITING","sponsor":"Swiss Tropical & Public Health Institute","isPivotal":false,"enrollment":120,"indication":"Sickle Cell Disease (SCD)","completionDate":"2029-12"},{"nctId":"NCT04389320","phase":"N/A","title":"Antimalarial and Covid 19 in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Assiut University","isPivotal":false,"enrollment":60,"indication":"Rheumatoid Arthritis","completionDate":"2020-05-01"},{"nctId":"NCT05192265","phase":"Phase 2","title":"Comparative Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine in The Treatment of Acute Uncomplicated Malaria Among Children In South-West Nigeria","status":"COMPLETED","sponsor":"University of Ibadan","isPivotal":true,"enrollment":172,"indication":"Malaria Fever, Plasmodium Falciparum Malaria","completionDate":"2020-12-23"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}